Literature DB >> 26421273

Persister mechanisms in Borrelia burgdorferi: implications for improved intervention.

Jie Feng1, Wanliang Shi1, Shuo Zhang1, Ying Zhang1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26421273      PMCID: PMC4576169          DOI: 10.1038/emi.2015.51

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


× No keyword cloud information.

Dear Editor, Lyme disease caused by Borrelia burgdorferi is the most common vector borne disease in the United States and Europe.[1,2] The current treatment for Lyme disease is a 2-4 week antibiotic monotherapy with doxycycline, amoxicillin or cefuroxime.[3] While this treatment is effective for the majority of Lyme disease patients, about 10%-20% of patients still have persisting symptoms such as fatigue, muscular pain, and neurological impairment even six months after the treatment,[1] a collection of symptoms called Post Treatment Lyme Disease Syndrome (PTLDS).[4] While the cause of PTLDS remains unclear and controversial, several hypotheses have been proposed to explain PTLDS, including host response to continued presence of bacterial debris,[5] autoimmunity,[6] co-infections,[7] and presence of bacterial persisters not killed by the current Lyme antibiotics.[7] Consistent with the persisting organisms not killed by current antibiotics, experiments in various animal models such as mice, dogs and monkeys have shown B. burgdorferi could still be detected after treatment with different Lyme antibiotics though viable organisms could not be cultured.[8,9,10] In vitro studies also demonstrated that B. burgdorferi could develop antibiotic tolerant persisters.[11] Although persister mechanisms have been reported in the model organism E. coli,[12] the mechanisms of B. burgdorferi persisters remain unknown. Here we performed RNA Sequencing (RNA-Seq) analysis to determine the gene expression profile of B. burgdorferi persisters that survived antibiotic treatment to shed light on the mechanisms of B. burgdorferi persistence. B. burgdorferi B31 cultures were grown for five days to 1×107 spirochetes/mL in Barbour-Stoenner-Kelly (BSK) BSK-H medium followed by treatment with 50 µg/mL doxycycline or 50 µg/mL amoxicillin for six days. Triplicate biological samples were used for each group. The total RNA was extracted and ribosomal RNA was removed prior to preparation of cDNA (complementary DNA) libraries for Illumina sequencing. We analyzed the up-regulated and down-regulated genes in the amoxicillin and doxycycline treated B. burgdorferi persisters compared with drug free control (Figure 1). The RNA-Seq data was analyzed by BLAST analysis and mapped to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Real-time quantitative reverse transcription PCR (RT-PCR) was performed for selected candidate genes that were upregulated (bmpD and clpP) or down-regulated (gene of membrane protein BB_0428 and rpmE) to validate the RNA-Seq data (see below).
Figure 1

Differentially expressed genes in doxycycline (A) and amoxicillin (B) tolerant B. burgdorferi persisters grouped into pathways. The green upward pentagons indicate upregulated genes, and the red downward pentagons indicate downregulated genes. Pathways in bold frame are differentially expressed in both doxycycline and amoxicillin tolerant persisters. Genes in bold type indicate genes that are shared in both doxycycline and amoxicillin tolerant persisters. Bb: B. burgdorferi.

For doxycycline treated B. burgdorferi persisters, a total of 675 genes were differentially expressed between doxycycline tolerant persisters and drug free group, with 335 genes upregulated and 340 genes down-regulated in doxycycline treated group. A total of 35 genes were identified by more than two-fold changes among up-regulated genes (Figure 1A), including five transporter genes (BB_0164, BB_0116, BB_0637, BB_0729 and BB_B29), four bacterial envelope protein coding genes (BB_0158, BB_A05, BB_0385 and BB_0201), three DNA repair related genes (BB_G32, BB_0552, BB_0830), two bacterial chemotaxis genes (BB_0114 and BB_0515), one bacterial secretion gene secD (BB_0652), and the clpP (BB_0757) gene encoding Clp protease. On the other hand, the majority of down-regulated (by more than two-fold) genes (33 genes) are associated with genes encoding outer membrane proteins and ribosome proteins. clpP encoding ATP-dependent Clp protease proteolytic subunit was the most highly upregulated (30 fold) in doxycycline tolerant B. burgdorferi persisters. ClpP protease is an intracellular protease which could recognize and degrade misfolded proteins with the aid of ClpX, C or A subunits. Doxycycline could disturb bacterial protein synthesis by binding to the 30S ribosomal subunit that might lead to misfolded proteins. The up-regulation of clpP could be a response to this situation. Meanwhile we also found some genes encoding heat shock proteins (HSP) were upregulated. The HSP molecular chaperones could stabilize proteins to ensure correct folding and help to refold damaged proteins under stress, which could be important for persister survival. Five up-regulated transporter genes (encoding phosphotransferase system, maltose and glucose uptake transporter, Na+/Ca2+ exchanger, dicarboxylate/amino acid uptake transporter and Na/H antiporter) could facilitate uptake of nutrients (carbohydrates and amino acid) and regulate intracellular ion concentration under the pressure of doxycycline. We also found some up-regulated genes are associated with DNA repair, which may help to maintain stability of DNA under the doxycycline stress. Cell structure proteins (envelope proteins) were biggest part of the total protein content, and inhibition of protein synthesis might cause cell envelope defect. We found most lipoproteins and outer membrane proteins were down-regulated, while the S1 and S2 antigens and some inner membrane proteins were up-regulated. The down-regulation of outer membrane lipoproteins could reduce a large demand for protein synthesis that would help B. burgdorferi persist under doxycycline stress. On the other hand, defect of outer membrane may allow strengthening of inner membrane structure by up-regulating membrane proteins. Ribosome is the target of doxycycline which inhibits protein synthesis. One persistence strategy of B. burgdorferi might be reducing the availability of drug targets. We found five ribosomal genes were down-regulated in the doxycycline treated B. burgdorferi persisters. Down-regulation of ribosome proteins may also reduce the metabolism and the demand for nutrients and energy, allowing cells to transition to persistence. For amoxicillin tolerant B. burgdorferi peristers, a total of 516 genes were differentially expressed compared with drug free control, with 342 genes being upregulated and 174 genes down-regulated. A total of 41 up-regulated genes and 45 down-regulated genes by more than two fold change were identified (Figure 1B). The up-regulated genes could be classified into membrane protein (BB_A05, BB_A36, BB_0385, BB_0767, BB_0844), bacterial chemotaxis (BB_0414, BB_0670, BB_0567), DNA repair (BB_0422, BB_0623 or mfd, BB_0344), energy production (BB_0782 or nadD), transporter (BB_0164, BB_0729), terpenoid/steroid synthesis (BB_0686, BB_0687), virulence (BB_A24, BB_A25 and BB_0766), Clp protease (BB_0757), and P450 family dehydrogenase (BB_G17). On the other hand, the majority of the down-regulated genes belong to outer membrane proteins (most are lipoproteins), ribosome proteins and glycolysis/gluconeogenesis. Comparison of the pathways of the doxycycline persisters and amoxicillin persisters revealed that they share several common features. For example, transporter (BB_0164, BB_0729), membrane protein (BB_A05, BB_0385), chemotaxis (BB_0414), ClpP protease (BB_0757), and DNA repair genes are up-regulated, while genes for outer membrane proteins/lipoproteins (BB_A61, BB_I39, BB_Q32) and ribosomal proteins (BB_0229) involved in protein synthesis were down-regulated. Besides these common pathways, genes for heat shock proteins and protein secretion protein were upregulated in doxycycline persisters, while amoxicillin persisters had virulence genes (dbpAB), terpenoid synthesis genes, and drug metabolism P450 family dehydrogenase gene uprgulated and glycolysis/gluconeogenesis genes down-regulated. These gene expression changes may play important roles in facilitating survival of B. burgdorferi persisters under antibiotic stress. Amoxicillin inhibits the synthesis of bacterial cell wall and induces B. burgdorferi into round body form.[13] In the amoxicillin tolerant persisters we also found many down-regulated outer membrane lipoprotein genes, which may provide a survival strategy for persisters. In addition, we found two terpenoid/steroid synthesis genes were up-regulated in amoxicillin tolerant presisters. B. burgdorferi is an unusual prokaryote that possesses sterols in its membranes.[14] Up-regulation of terpenoid/steroid synthesis genes in amoxicillin tolerant persisters may increase the content of sterols, and change the cell membrane component to allow survival under amoxicillin treatment. B. burgdorferi decorin-binding proteins (Dbp) A (BB_A24) and B (BB_A25) are mainly expressed during mammalian infection to mediate bacterial attachment to the proteoglycan decorin in decorin-expressing mammal cells.[15] The elevated dbpAB expression in B. burgdorferi persisters without mammalian infection by amoxicillin treatment may enhance interaction with host cell and promote pathogen persistence. Our findings not only shed new light on the mechanisms of B. burgdorferi persisters but also have practical applications. For example, the upregulated genes identified in B. burgdorferi persisters may not only serve as targets for developing new drugs for more effective treatment but also antigens for developing diagnostic tests for persistent Lyme disease, and finally for developing therapeutic vaccines for improved treatment. Future studies are needed to address these possibilities for more effective control of Lyme disease.
  13 in total

1.  Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.

Authors:  Linda K Bockenstedt; David G Gonzalez; Ann M Haberman; Alexia A Belperron
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

Review 2.  Lyme borreliosis in Europe.

Authors:  A Rizzoli; Hc Hauffe; G Carpi; Gi Vourc H; M Neteler; R Rosa
Journal:  Euro Surveill       Date:  2011-07-07

3.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

4.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 6.  Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis.

Authors:  A C Steere; D Gross; A L Meyer; B T Huber
Journal:  J Autoimmun       Date:  2001-05       Impact factor: 7.094

7.  Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.

Authors:  Monica E Embers; Stephen W Barthold; Juan T Borda; Lisa Bowers; Lara Doyle; Emir Hodzic; Mary B Jacobs; Nicole R Hasenkampf; Dale S Martin; Sukanya Narasimhan; Kathrine M Phillippi-Falkenstein; Jeanette E Purcell; Marion S Ratterree; Mario T Philipp
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

Review 8.  Persisters, persistent infections and the Yin-Yang model.

Authors:  Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2014-01-08       Impact factor: 7.163

9.  Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.

Authors:  Jie Feng; Ting Wang; Wanliang Shi; Shuo Zhang; David Sullivan; Paul G Auwaerter; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2014-07-02       Impact factor: 7.163

10.  Proving lipid rafts exist: membrane domains in the prokaryote Borrelia burgdorferi have the same properties as eukaryotic lipid rafts.

Authors:  Timothy J LaRocca; Priyadarshini Pathak; Salvatore Chiantia; Alvaro Toledo; John R Silvius; Jorge L Benach; Erwin London
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

View more
  15 in total

Review 1.  Sleeper cells: the stringent response and persistence in the Borreliella (Borrelia) burgdorferi enzootic cycle.

Authors:  Felipe C Cabello; Henry P Godfrey; Julia V Bugrysheva; Stuart A Newman
Journal:  Environ Microbiol       Date:  2017-09-11       Impact factor: 5.491

2.  Generality of Post-Antimicrobial Treatment Persistence of Borrelia burgdorferi Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.

Authors:  Emir Hodzic; Denise M Imai; Edlin Escobar
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

3.  Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.

Authors:  Richard I Horowitz; Phyllis R Freeman
Journal:  Antibiotics (Basel)       Date:  2022-07-07

Review 4.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

5.  Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime.

Authors:  Jie Feng; Megan Weitner; Wanliang Shi; Shuo Zhang; Ying Zhang
Journal:  Front Microbiol       Date:  2016-02-10       Impact factor: 5.640

6.  Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony B. burgdorferi Persisters Which Are Sterilized by Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing.

Authors:  Jie Feng; Shuo Zhang; Wanliang Shi; Ying Zhang
Journal:  Front Microbiol       Date:  2016-11-04       Impact factor: 5.640

7.  Activity of Sulfa Drugs and Their Combinations against Stationary Phase B. burgdorferi In Vitro.

Authors:  Jie Feng; Shuo Zhang; Wanliang Shi; Ying Zhang
Journal:  Antibiotics (Basel)       Date:  2017-03-22

Review 8.  When a patient suspected with juvenile idiopathic arthritis turns out to be diagnosed with an infectious disease - a review of Lyme arthritis in children.

Authors:  Krzysztof Orczyk; Joanna Świdrowska-Jaros; Elżbieta Smolewska
Journal:  Pediatr Rheumatol Online J       Date:  2017-05-08       Impact factor: 3.054

9.  Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library.

Authors:  Jie Feng; Megan Weitner; Wanliang Shi; Shuo Zhang; David Sullivan; Ying Zhang
Journal:  Antibiotics (Basel)       Date:  2015-09-16

10.  Lyme disease: the promise of Big Data, companion diagnostics and precision medicine.

Authors:  Raphael B Stricker; Lorraine Johnson
Journal:  Infect Drug Resist       Date:  2016-09-13       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.